Literature DB >> 21184618

Standardizing the inclusion of indirect medical costs in economic evaluations.

Pieter H M van Baal1, Albert Wong, Laurentius C J Slobbe, Johan J Polder, Werner B F Brouwer, G Ardine de Wit.   

Abstract

A shortcoming of many economic evaluations is that they do not include all medical costs in life-years gained (also termed indirect medical costs). One of the reasons for this is the practical difficulties in the estimation of these costs. While some methods have been proposed to estimate indirect medical costs in a standardized manner, these methods fail to take into account that not all costs in life-years gained can be estimated in such a way. Costs in life-years gained caused by diseases related to the intervention are difficult to estimate in a standardized manner and should always be explicitly modelled. However, costs of all other (unrelated) diseases in life-years gained can be estimated in such a way. We propose a conceptual model of how to estimate costs of unrelated diseases in life-years gained in a standardized manner. Furthermore, we describe how we estimated the parameters of this conceptual model using various data sources and studies conducted in the Netherlands. Results of the estimates are embedded in a software package called 'Practical Application to Include future Disease costs' (PAID 1.0). PAID 1.0 is available as a Microsoft® Excel tool (available as Supplemental Digital Content via a link in this article) and enables researchers to 'switch off' those disease categories that were already included in their own analysis and to estimate future healthcare costs of all other diseases for incorporation in their economic evaluations. We assumed that total healthcare expenditure can be explained by age, sex and time to death, while the relationship between costs and these three variables differs per disease. To estimate values for age- and sex-specific per capita health expenditure per disease and healthcare provider stratified by time to death we used Dutch cost-of-illness (COI) data for the year 2005 as a backbone. The COI data consisted of age- and sex-specific per capita health expenditure uniquely attributed to 107 disease categories and eight healthcare provider categories. Since the Dutch COI figures do not distinguish between costs of those who die at a certain age (decedents) and those who survive that age (survivors), we decomposed average per capita expenditure into parts that are attributable to decedents and survivors, respectively, using other data sources.

Entities:  

Mesh:

Year:  2011        PMID: 21184618     DOI: 10.2165/11586130-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  24 in total

1.  Does prevention save costs? Considering deferral of the expensive last year of life.

Authors:  Afschin Gandjour; Karl Wilhelm Lauterbach
Journal:  J Health Econ       Date:  2005-03-20       Impact factor: 3.883

Review 2.  Counting backward to health care's future: using time-to-death modeling to identify changes in end-of-life morbidity and the impact of aging on health care expenditures.

Authors:  Greg Payne; Audrey Laporte; Raisa Deber; Peter C Coyte
Journal:  Milbank Q       Date:  2007-06       Impact factor: 4.911

3.  Future costs in cost effectiveness analysis.

Authors:  Robert H Lee
Journal:  J Health Econ       Date:  2007-12-07       Impact factor: 3.883

4.  Aging, health expenditure, proximity to death, and income in Finland.

Authors:  Unto Häkkinen; Pekka Martikainen; Anja Noro; Elina Nihtilä; Mikko Peltola
Journal:  Health Econ Policy Law       Date:  2008-04

5.  Future costs in economic evaluation. A comment on Lee.

Authors:  Talitha L Feenstra; Pieter H M van Baal; Afshin Gandjour; Werner B F Brouwer
Journal:  J Health Econ       Date:  2008-07-25       Impact factor: 3.883

6.  Health care costs in the last year of life--the Dutch experience.

Authors:  Johan J Polder; Jan J Barendregt; Hans van Oers
Journal:  Soc Sci Med       Date:  2006-06-14       Impact factor: 4.634

7.  Effect of future costs on cost-effectiveness of medical interventions among young adults: the example of intensive therapy for type 1 diabetes mellitus.

Authors:  D Meltzer; B Egleston; D Stoffel; E Dasbach
Journal:  Med Care       Date:  2000-06       Impact factor: 2.983

8.  Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care.

Authors:  Braden Manns; David Meltzer; Ken Taub; Cam Donaldson
Journal:  Health Econ       Date:  2003-11       Impact factor: 3.046

9.  Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study.

Authors:  W J Meerding; L Bonneux; J J Polder; M A Koopmanschap; P J van der Maas
Journal:  BMJ       Date:  1998-07-11

10.  The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening.

Authors:  I M C M de Kok; J J Polder; J D F Habbema; L-M Berkers; W J Meerding; M Rebolj; M van Ballegooijen
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

View more
  28 in total

1.  Including indirect medical care costs from survivor years of life in economic evaluations.

Authors:  John A Nyman; Hawre J Jalal
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

2.  PAID 1.0 in practice: a brief clarification regarding its possibilities and limitations.

Authors:  Pieter van Baal; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2011-06       Impact factor: 4.981

3.  Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et Al.

Authors:  Pieter van Baal; David Meltzer; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

4.  From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.

Authors:  Matthijs Versteegh; Saskia Knies; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2016-11       Impact factor: 4.981

5.  Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.

Authors:  Michelle Tew; Philip Clarke; Karin Thursky; Kim Dalziel
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

6.  Future Offspring Costs in Economic Evaluation.

Authors:  Evelyn Verbeke; Jeroen Luyten
Journal:  Pharmacoeconomics       Date:  2021-10-29       Impact factor: 4.981

7.  Future medical and non-medical costs and their impact on the cost-effectiveness of life-prolonging interventions: a comparison of five European countries.

Authors:  Hamraz Mokri; Ingelin Kvamme; Linda de Vries; Matthijs Versteegh; Pieter van Baal
Journal:  Eur J Health Econ       Date:  2022-08-04

8.  Comparison of the Financial Burden of Survivors of Head and Neck Cancer With Other Cancer Survivors.

Authors:  Sean T Massa; Nosayaba Osazuwa-Peters; Eric Adjei Boakye; Ronald J Walker; Gregory M Ward
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2019-03-01       Impact factor: 6.223

9.  Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis.

Authors:  Blanca Gros; Antonio Galán; Emilio González-Parra; Jose A Herrero; Maria Echave; Stefan Vegter; Keith Tolley; Itziar Oyagüez
Journal:  Health Econ Rev       Date:  2015-06-11

10.  Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening.

Authors:  Astrid Langer; Rolf Holle; Jürgen John
Journal:  BMC Health Serv Res       Date:  2012-09-04       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.